Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00392327 · OUTCOME

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET · Source last updated 2026-06-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
T-Score
Interval / dispersion
Standard Deviation
Time frame
6 - 12 months post diagnosis

What was measured

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. Mean and standard deviation of MI were calculated and reported.

Analysis population: Eligible medulloblastoma patients are included.

Groups in this outcome

Regimen A (Medulloblastoma Patients)

Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)

Regimen B (Medulloblastoma Patients)

Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)

Regimen C (Medulloblastoma Patients)

Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)

Regimen D (Medulloblastoma Patients)

Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen A (Medulloblastoma Patients)20
Regimen B (Medulloblastoma Patients)27
Regimen C (Medulloblastoma Patients)11
Regimen D (Medulloblastoma Patients)17

Reported measurements

Source class 1
Values in T-Score · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Regimen A (Medulloblastoma Patients)50.911.32Not reportedNot reportedNot reported
Regimen B (Medulloblastoma Patients)50.211.92Not reportedNot reportedNot reported
Regimen C (Medulloblastoma Patients)50.810.04Not reportedNot reportedNot reported
Regimen D (Medulloblastoma Patients)47.58.25Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        11.32
        value
        50.9
      2. group Id
        OG001
        spread
        11.92
        value
        50.2
      3. group Id
        OG002
        spread
        10.04
        value
        50.8
      4. group Id
        OG003
        spread
        8.25
        value
        47.5
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    2. group Id
      OG001
      value
      27
    3. group Id
      OG002
      value
      11
    4. group Id
      OG003
      value
      17
    units
    Participants
description
Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. Mean and standard deviation of MI were calculated and reported.
dispersion Type
Standard Deviation
groups
  1. description
    Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)
    id
    OG000
    title
    Regimen A (Medulloblastoma Patients)
  2. description
    Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)
    id
    OG001
    title
    Regimen B (Medulloblastoma Patients)
  3. description
    Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)
    id
    OG002
    title
    Regimen C (Medulloblastoma Patients)
  4. description
    Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)
    id
    OG003
    title
    Regimen D (Medulloblastoma Patients)
param Type
MEAN
population Description
Eligible medulloblastoma patients are included.
reporting Status
POSTED
time Frame
6 - 12 months post diagnosis
title
Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients
type
SECONDARY
unit Of Measure
T-Score

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice